Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
RMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$179.42 - $263.05
Previous CloseN/A
Volume178.41K
Average Volume (3M)1.22M
Market Cap
$34.33B
Enterprise Value$32.86B
Total Cash (Recent Filing)$237.91M
Total Debt (Recent Filing)$1.17B
Price to Earnings (P/E)26.3
Beta1.14
Next Earnings
Jul 31, 2025EPS Estimate
2.48Next Dividend Ex-Date
May 08, 2025Dividend Yield0.88%
Share Statistics
EPS (TTM)8.91
Shares Outstanding146,627,400
10 Day Avg. Volume1,413,253
30 Day Avg. Volume1,217,926
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.38
Enterprise Value/Ebitda19.88
Forecast
1Y Price Target
$264.44Price Target Upside11.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company experienced a 140 basis points gross margin expansion, reaching a level not seen since 2Q21, indicating strong financial performance.
Share Buyback ProgramStrong cash generation has allowed Resmed to extend its buyback program, increasing it to $100 million per quarter, which is a positive signal to investors.
Tariff ExemptionResmed confirms CPAP products are exempt from tariffs under the Nairobi Protocol, which is a favorable development for the company.
Bears Say
GLP-1 Drug RiskGiven the risk posed by the FDA approval of the first GLP-1 drug for obstructive sleep apnea (OSA) and Medicare's coverage of the drug for OSA, we maintain our Hold rating.
GLP-1 Medications ChallengeThe increasing prominence of GLP-1 medications is expected to pose several challenges for the CPAP market.
Tariff ImpactA 10% baseline tariff applied to AUS and SNG products could negatively impact Resmed Inc's financial performance.
---
Ownership Overview
0.52% Insiders
17.00% Mutual Funds
0.66% Other Institutional Investors
57.44% Public Companies and
Individual Investors
RMD FAQ
What was Resmed’s price range in the past 12 months?
Resmed lowest stock price was $179.42 and its highest was $263.05 in the past 12 months.
What is Resmed’s market cap?
Resmed’s market cap is $34.33B.
When is Resmed’s upcoming earnings report date?
Resmed’s upcoming earnings report date is Jul 31, 2025 which is in 92 days.
How were Resmed’s earnings last quarter?
Resmed released its earnings results on Apr 23, 2025. The company reported $2.37 earnings per share for the quarter, missing the consensus estimate of $2.378 by -$0.008.
Is Resmed overvalued?
According to Wall Street analysts Resmed’s price is currently Undervalued.
Does Resmed pay dividends?
Resmed pays a Quarterly dividend of $2.066 which represents an annual dividend yield of 0.88%. See more information on Resmed dividends here
What is Resmed’s EPS estimate?
Resmed’s EPS estimate is 2.48.
How many shares outstanding does Resmed have?
Resmed has 146,627,400 shares outstanding.
What happened to Resmed’s price movement after its last earnings report?
Resmed reported an EPS of $2.37 in its last earnings report, missing expectations of $2.378. Following the earnings report the stock price went up 10.101%.
Which hedge fund is a major shareholder of Resmed?
Currently, no hedge funds are holding shares in RMD
---
Resmed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$264.44 (11.23% Upside)
$264.44 (11.23% Upside)
Blogger Sentiment
Bullish
RMD Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $499.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.45%
12-Months-Change
Fundamentals
Return on Equity
25.81%
Trailing 12-Months
Asset Growth
11.04%
Trailing 12-Months
Company Description
Resmed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
---
RMD Company Deck
---
RMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, gross margin expansion, successful product launches, and increased share buybacks. Despite challenges such as sleep lab backlogs and foreign currency impacts, ResMed demonstrated resilience with strategic expansions and maintaining tariff exemptions.Read More>---
RMD Revenue Breakdown
87.53% Sleep and Respiratory Care
12.47% Software as a Service
---
RMD Stock 12 Month Forecast
Average Price Target
$264.44
▲(11.23% Upside)
Technical Analysis
---